BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn in amyotrophic lateral sclerosis patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem. The study achieved its primary endpoint in demonstrating that NurOwn is safe and well-tolerated at doses up to 2 million cells per kilogram administered intrathecally and 48 million cells administered intramuscularly .
http://ift.tt/1s0AThN
http://ift.tt/1s0AThN
No comments:
Post a Comment